Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.
about
Multimodal management of muscle-invasive bladder cancerOne-step extrapolation of the prediction performance of a gene signature derived from a small studyTranscriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis.Competing risks data analysis with high-dimensional covariates: an application in bladder cancer.Predicting the Survival Time for Bladder Cancer Using an Additive Hazards Model in Microarray Data.Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis.A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting.Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma.High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.Biomarkers for bladder cancer management: present and future.HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma.Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancerModelling bladder cancer in mice: opportunities and challenges.Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype CarcinomasUrothelial cancer gene regulatory networks inferred from large-scale RNAseq, Bead and Oligo gene expression data.An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancerIdentification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaThe cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinomaBladder cancer: a simple model becomes complex.Genetic evaluation of male infertility.Selecting cases for whom additional tests can improve prognostication.E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder CancerUrinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancerCLT1 targets bladder cancer through integrin α5β1 and CLIC3Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma.FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.Ruguo key genes and tumor driving factors identification of bladder cancer based on the RNA-seq profile.Nomogram based on systemic inflammatory response markers predicting the survival of patients with resectable gastric cancer after D2 gastrectomy.Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation.An essential role for decorin in bladder cancer invasiveness.Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2.Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patientsIntegrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer.Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy.Gene expression profiling in bladder cancer identifies potential therapeutic targets
P2860
Q27011624-73BA61D0-CA0C-47E0-BCF7-9BD037D33F38Q28392088-7F1CA257-B36F-42A7-B1CC-26309EA73E5AQ30416201-058BA52E-0EFD-4F03-B684-8B6709A040FCQ30485940-E7F84994-5F83-4FD0-B387-4B5CF94C9701Q30838620-D24264AB-6904-45BB-B0C2-D4CDCA211F08Q30938790-0377CD67-2520-4590-B158-E43BE74858A3Q31085072-A9F307DA-A7B5-47C8-805D-D9CFDF988F3CQ31089944-068AEC83-589E-4AAF-8221-58D129FF2A64Q33439263-F5CCCA20-769F-4382-8FDC-3319E2DBD871Q33784670-2EA0CF41-32B8-4507-B1E2-64AC7D905E09Q34184763-ACB84318-D40F-4858-A1EF-1ED1F7063859Q34448168-685B87C1-0EF6-450D-9CAF-4538894A3F2BQ34474418-D8318176-6165-477B-8C45-3E65E1BC7416Q34563208-83065886-2963-4693-86C5-40F16AEF566DQ35285703-8B1CF705-BF5F-48CC-9E51-3B75A5DF1A0CQ35612218-F82E2B47-5FB9-45ED-BE78-9C6D2C3DB707Q35630898-A5ECE456-43D8-446A-9FDE-92B7150C8B92Q35678922-0209A2D4-8D47-4C51-A7E6-370FB9D63C73Q35731224-D19E96E2-4C06-48A5-908E-191FD0C91325Q35832332-235FA9D8-65F3-48A6-A0B3-AC38728697FBQ36108115-E4D10DFF-86CB-4268-9F87-3C46D6276B02Q36450914-DD51FD64-EC5A-452E-AB51-D16BF5CCFC70Q36519219-6E2288F5-6A39-454B-A3BA-D69EB853F77BQ36526008-FF304B46-2E50-4282-BAB1-3F0D31E3C75BQ36547455-0D285230-B7ED-41A9-8077-989491D4746CQ36628548-4096A0F5-A314-4D81-9668-4CF4AF793C56Q36853876-4EEC2DCF-758B-4AC4-B78A-88FDB633B071Q36882005-48E8F6B9-4020-4AB2-B983-5E6D0FF333F3Q36891229-F3AA8835-F339-4213-AA45-62E8FC12BAB8Q37437217-7A8D0A16-9C15-41A6-A3F7-6B3E1AB41F47Q37478633-FBABE840-948F-475A-9A0A-58B1B128B02FQ37536495-A048D869-FD9B-4A0D-A0C2-2FAB246AC521Q37557168-59619BF6-AE6E-4EF6-867D-0CCFABA965A7Q37612632-94F79599-FB96-48CB-861F-BE6272B7AF02Q37622196-EDE59B60-B733-409C-A804-B18693C96EC0Q37663875-8E8AFC1E-9654-46F2-8249-0079DF826178Q37684594-CE7AF8F2-2463-4B27-9DEC-377BB1FC9EDEQ37702349-99D73ADF-67E7-4700-A423-F084A7D4C8DBQ37713409-5F50FB8D-6906-44D8-A6B3-FA8C9684D05AQ37718676-74B6ABED-5D30-47BC-860D-7C725C1C45C9
P2860
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Combination of a novel gene ex ...... l in high-risk bladder cancer.
@ast
Combination of a novel gene ex ...... l in high-risk bladder cancer.
@en
type
label
Combination of a novel gene ex ...... l in high-risk bladder cancer.
@ast
Combination of a novel gene ex ...... l in high-risk bladder cancer.
@en
prefLabel
Combination of a novel gene ex ...... l in high-risk bladder cancer.
@ast
Combination of a novel gene ex ...... l in high-risk bladder cancer.
@en
P2093
P2860
P50
P1476
Combination of a novel gene ex ...... al in high-risk bladder cancer
@en
P2093
Andrew Feifer
Franziska Michor
Jennifer M Taylor
Robert J Downey
Theresa Koppie
P2860
P304
P356
10.1158/1078-0432.CCR-11-2271
P407
P577
2012-01-06T00:00:00Z